Fetal Alcohol Syndrome Clinical Trial
— B4Z-MC-X017Official title:
A Study of the Efficacy of Atomoxetine in Treating the Inattention, Impulsivity and Hyperactivity in Children With Fetal Alcohol Syndrome or Effects
Verified date | April 2017 |
Source | University of Oklahoma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine if atomoxetine hydrochloride improves inattention, hyperactivity, and impulsivity problems in children exposed to alcohol during birth.
Status | Completed |
Enrollment | 38 |
Est. completion date | April 22, 2015 |
Est. primary completion date | April 22, 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 11 Years |
Eligibility |
Inclusion Criteria: - Patient must be between the ages of 4 and 11 years at the time of entry into the study. - Patients must meet diagnostic criteria for FASD - Patient must meet DSM-IV criteria for ADHD, any subtype and must have an ADHDRS-IV score of > or = to 90%ile for age and gender for either subtest or total score if greater than 5 years of age. - Patients who enter the study at visit 1 taking stimulant medication must be medication-free for at least 24 hours before visit 2. - History and physical exam must reveal no clinically significant abnormalities that would preclude safe participation in the study. - Patients must be able to swallow capsules. - Patients must be of a sufficient developmental level (~3 yrs) to participate in the study. - Patients and parents must be able to communicate effectively with the investigator and coordinator and be judged reliable to keep appointments and participate in data collection. - Teacher must agree to cooperate with the study. Children less than 6 years old must have completed a course of PCIT and still meet DSM-IV criteria for ADHD. Exclusion Criteria: - Have received an in investigational medication in the past 30 days. - Are currently on a medication treatment that is effective (ADHDRS-IV score within 1 SD of average) and well tolerated. - Have significant current medical conditions that could be exacerbated or compromised by atomoxetine. - Have used MAOIs within one month prior to visit 2. - Patients with hypertension. - Patients with a previous diagnosis of bipolar disorder, psychosis, or autism spectrum disorder. - Patients taking anticonvulsants for seizure control. - Patients taking another psychotropic medication or health food supplements purported to have central nervous system activity within 5 half-lives of visit 2. - Patients with Tourette Disorder or any other neurological condition that would interfere with their ability to receive treatment or comply with monitoring. - Pubertal girls. |
Country | Name | City | State |
---|---|---|---|
United States | OU Child Study Center | Oklahoma City | Oklahoma |
Lead Sponsor | Collaborator |
---|---|
University of Oklahoma | Eli Lilly and Company, Mark L. Wolraich, M.D. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | ADHD Rating Scale - IV | length of protocol | ||
Secondary | Determine if atomoxetine is safe and well tolerated by children with FAS. | length of protocol | ||
Secondary | Determine if atomoxetine is effective in both school and home, and significantly reduces symptoms of inattention, hyperactivity, and impulsivity in children with FAS compared to children with FAS receiving placebo. | length of protocol | ||
Secondary | Determine if atomoxetine improves behaviors in the mornings and evenings. | Length of protocol | ||
Secondary | Determine if parents of children with FAS are satisfied with the effectiveness of atomoxetine. | Length of protocol | ||
Secondary | Determine if there are any differences in the adverse effects profile of children with FAS compared to the overall profile for atomoxetine. | Length of protocol | ||
Secondary | Determine the degree of functional limitation experienced by this group of children with FAS and whether this impairment is decreased by treatment with atomoxetine as demonstrated by the Pediatric Evaluation of Disability Inventory (PEDI) | Length of protocol |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06163651 -
Evaluating a One-Year Version of the Parent-Child Assistance Program
|
N/A | |
Active, not recruiting |
NCT00996528 -
Neighborhood Alcohol & HIV Prevention in South African Townships (Philani)
|
Phase 3 | |
Completed |
NCT00164554 -
Fetal Alcohol Syndrome/ARND Research Consortion
|
Phase 1/Phase 2 | |
Completed |
NCT00164229 -
Fetal Alcohol Syndrome: Socio-Cognitive Habilitation
|
Phase 1/Phase 2 | |
Recruiting |
NCT05534568 -
The Oklahoma Parent-Child Assistance Program
|
N/A | |
Recruiting |
NCT05385328 -
Multisensorial Analysis of Human Activity for Diagnosis and Early Detection of Functional Limitations
|
||
Completed |
NCT01911299 -
Choline Supplementation in Children With Fetal Alcohol Spectrum Disorders
|
Phase 2 | |
Terminated |
NCT00747630 -
Evaluating the Efficacy of a Video Based Intervention to Educate Teen Moms About Fetal Alcohol Syndrome (FAS)
|
Phase 0 | |
Recruiting |
NCT04332172 -
Scaling Up: A Multi-Site Trial of e-SBI for Alcohol Use in Pregnancy
|
N/A | |
Completed |
NCT00696085 -
Fetal Alcohol Damage Prevention Study
|
N/A | |
Recruiting |
NCT00418262 -
Open-Label Study of the Long Term Tolerability and Safety of Atomoxetine in Children With FASD and ADD/ADHD
|
Phase 3 | |
Completed |
NCT01149538 -
Postnatal Choline Supplementation in Children With Prenatal Alcohol Exposure
|
Phase 1/Phase 2 | |
Recruiting |
NCT03371641 -
In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions
|
N/A | |
Completed |
NCT00164346 -
Neurocognitive Habilitation for Children With Fetal Alcohol Syndrome (FAS)/Alcohol-Related Neurodevelopmental Disorder (ARND)
|
Phase 1/Phase 2 | |
Completed |
NCT01994603 -
Expansion to Interdisciplinary HIV Prevention in Women
|
N/A | |
Completed |
NCT02600624 -
Prenatal Alcohol Biomarker Study in Uruguay
|
||
Completed |
NCT00244062 -
Healthy Moms Alcohol Intervention
|
N/A | |
Recruiting |
NCT04395196 -
RCT of Prenatal Choline Supplementation During Pregnancy to Mitigate Adverse Effects of Prenatal Alcohol Exposure
|
Phase 2 |